Imbalance of interleukin‐17‐producing <scp>CD</scp>4 <scp>T</scp> cells/regulatory <scp>T</scp> cells axis occurs in remission stage of patients with hepatitis <scp>B</scp> virus‐related acute‐on‐chronic liver failure

Geng‐Lin Zhang,Dong‐Ying Xie,Bing‐Liang Lin,Chan Xie,Yi‐Nong Ye,Liang Peng,Shao‐Quan Zhang,Yu‐Feng Zhang,Qing Lai,Jian‐Yun Zhu,Ying Zhang,Yang‐Su Huang,Zhao‐Xia Hu,Zhi‐Liang Gao
DOI: https://doi.org/10.1111/jgh.12082
2013-01-01
Journal of Gastroenterology and Hepatology
Abstract:AbstractBackground and AimAlthough regulatory T cells (Treg) and interleukin‐17‐producing CD4 T cells (Th17) have been demonstrated to play opposing roles in inflammation‐associated diseases, their frequency and balance in different stages of hepatitis B virus (HBV)‐related acute‐on‐chronic liver failure (ACLF) remain unknown.MethodsFourteen patients with HBV‐associated ACLF were studied and defined into different stages according to disease activity. Circulating Th17 cells and Treg cells were analyzed by flow cytometry, and the cytokines were quantitated by enzyme‐linked immunosorbent assay. Results were correlated with temporal changes in viral load, disease progression and compared with 30 chronic hepatitis B (CHB) subjects and 18 healthy subjects.ResultsWe showed a significantly higher frequency of circulating Th17 cells in the remission stage of ACLF when compared with the progression stage, the CHB group, or normal controls. However, the frequency of circulating Treg cells was significantly lower in the remission stage of ACLF when compared with the progression stage or the CHB group. The increase in Th17 cells and concomitant decrease in Treg cells created an imbalance in the remission stage of ACLF patients, which negatively correlated with disease progression. In addition, we showed that ACLF patients in the remission stage had an altered profile of cytokines that regulated the induction of Th17 cells and Treg cells.ConclusionsACLF patients in the remission stage had an imbalance of Th17 to Treg cells, which could be used as a prognostic marker to predict disease progression. This imbalance could play a role in the immunopathogenesis of HBV‐related ACLF.
What problem does this paper attempt to address?